Serac Healthcare
Serac Life Sciences is dedicated to developing innovative molecular imaging technologies through its two wholly owned subsidiaries, Serac Healthcare and Serac Imaging Systems. The company's mission is to bring better care and quality of life to patients worldwide by advancing game-changing imaging agents and devices, such as 99mTc-maraciclatide and Seracam®, to improve diagnosis and treatment of conditions like endometriosis, rheumatoid arthritis, and other inflammatory diseases.
Industries
Nr. of Employees
small (1-50)
Serac Healthcare
6th Floor, Charlotte Building, 17 Gresse Street, London W1T 1QL
Products
Investigational technetium-99m integrin-targeting SPECT-CT imaging agent (investigational diagnostic)
A technetium-99m labelled radiotracer that targets αvβ3 integrin, developed for visualisation of superficial peritoneal endometriosis and inflammatory arthritis; currently in clinical studies and regulatory review pathways.
Portable hybrid gamma-optical camera for point-of-care imaging (investigational)
A miniaturised, high-resolution gamma camera integrated with real‑time optical video fusion to enable bedside molecular imaging and improve workflow in nuclear medicine departments; subject to clinical evaluation and comparative testing.
Investigational technetium-99m integrin-targeting SPECT-CT imaging agent (investigational diagnostic)
A technetium-99m labelled radiotracer that targets αvβ3 integrin, developed for visualisation of superficial peritoneal endometriosis and inflammatory arthritis; currently in clinical studies and regulatory review pathways.
Portable hybrid gamma-optical camera for point-of-care imaging (investigational)
A miniaturised, high-resolution gamma camera integrated with real‑time optical video fusion to enable bedside molecular imaging and improve workflow in nuclear medicine departments; subject to clinical evaluation and comparative testing.
Services
Partnered planning and execution of clinical imaging studies (Phase I–II), including investigator‑led multicentre trials and patient scanning.
Technical characterisation studies and head‑to‑head comparative imaging evaluations versus standard gamma cameras, with peer‑reviewed publication of results.
Development and validation of deep learning models for automated segmentation and classification of nuclear medicine images to identify regions of inflammation and support quantitative assessment.
Partnered planning and execution of clinical imaging studies (Phase I–II), including investigator‑led multicentre trials and patient scanning.
Technical characterisation studies and head‑to‑head comparative imaging evaluations versus standard gamma cameras, with peer‑reviewed publication of results.
Development and validation of deep learning models for automated segmentation and classification of nuclear medicine images to identify regions of inflammation and support quantitative assessment.
Expertise Areas
- Radiopharmaceutical development
- Molecular imaging device development
- Clinical trial management for imaging agents
- Image analysis and AI for nuclear medicine
Key Technologies
- Technetium-99m SPECT radiotracer labelling
- Integrin-targeted radiotracers
- Hybrid gamma-optical imaging
- SPECT-CT imaging
News & Updates
Serac Healthcare Limited and the University of Exeter announce the start of a Phase II study evaluating 99mTc-maraciclatide in interstitial lung disease.
Results from a study evaluating 99mTc-maraciclatide for endometriosis.
An abstract on Seracam® for sentinel lymph node imaging was accepted at SNMMI.
Positive feedback on Phase III trial design for endometriosis imaging agent.
An abstract on detecting endometriosis expressed integrins using technetium-99m was accepted for presentation.
A presentation on the DETECT study at EANM’24.
Serac Healthcare Limited and the University of Exeter announce the start of a Phase II study evaluating 99mTc-maraciclatide in interstitial lung disease.
Results from a study evaluating 99mTc-maraciclatide for endometriosis.
An abstract on Seracam® for sentinel lymph node imaging was accepted at SNMMI.
Positive feedback on Phase III trial design for endometriosis imaging agent.
An abstract on detecting endometriosis expressed integrins using technetium-99m was accepted for presentation.
A presentation on the DETECT study at EANM’24.